CD274 and neoplasm: Based on the results of several key phase III clinical trials, the latest National Comprehensive Cancer Network (NCCN) guidelines stated that nivolumab and atezolizumab can be used in patients with non-sensitive mutant NSCLC as second-line treatment and that pembrolizumab can be used as second-line treatment in patients who have PD-L1 expression in ≥1% tumour cells or as first-line treatment in patients who have PD-L1 expression in ≥50% tumour cells4–8.